Key Takeaways
- •ARA-290, also called cibinetide, is an eleven-residue peptide from the helix B domain of erythropoietin, sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, with CAS 1208243-50-8, formula C51H84N16O21 and an average mass of 1257.3 g/mol.
- •It is non-erythropoietic by design. The helix B surface is the face of EPO that does not contact the classical receptor, so the peptide does not reproduce EPO's effect on red cell production.
- •Its proposed target is a heteromeric receptor, described in the literature as the innate repair receptor, rather than the EPO receptor homodimer that drives erythropoiesis.
- •The N-terminus is a pyroglutamate, which is why one of its names is PHBSP, pyroglutamate helix B surface peptide. That cyclized residue is both deliberate here and a common degradation artifact elsewhere.
- •Clinical development reached phase 2 and stopped, with no marketing authorization anywhere. No registered trial has a start date after 2016, one was terminated and one has unknown status. FDA's May 2026 compounding list places cibinetide (ARA-290) in Category 3, substances nominated without adequate support, and it is not among the six peptides in the October 2026 HHS draft policy.
- •The recurring human endpoint is a structural surrogate, corneal nerve fibre measurement, not a clinical outcome. In the largest trial, 64 participants over 28 days, it reached significance in one of three active arms, and pain scores improved in every group including placebo.
Summary
ARA-290, also called cibinetide, is an eleven-residue peptide copied from a surface of erythropoietin that does not touch the receptor behind red cell production, so by design it does not act like EPO. Its clinical programme reached phase 2, with four registered trials of 64 participants or fewer, and no trial has started since 2016. The recurring human endpoint was a corneal nerve fibre measurement, a structural surrogate rather than a clinical outcome. It holds no marketing authorization anywhere, and the FDA's May 2026 compounding list places it in Category 3.
ARA-290 is derived from erythropoietin, which leads most readers to exactly the wrong conclusion. The molecule was engineered specifically so that it would not do what EPO is famous for: it carries no erythropoietic activity and does not raise red cell mass. Separating the tissue-protective signalling from the blood-forming signalling was the entire design objective, and the eleven-residue peptide is what came out of it.
This guide covers what ARA-290 is, why an EPO-derived peptide can lack EPO's defining activity, exactly what the four registered clinical trials measured and where development stopped, where it stands with the FDA in 2026, and how to verify a lot of a peptide with a cyclised N-terminus. It is written for laboratory and in-vitro research procurement. It reports what published studies recorded because that is the public evidence base, and it contains no dosing, administration or human-use guidance, and none should be inferred.
What ARA-290 Is
Erythropoietin is a 165-residue glycoprotein hormone. ARA-290 is an eleven-residue peptide corresponding to a surface region of its helix B domain.
| Property | Value |
|---|---|
| Other names | Cibinetide, ARA290, PHBSP |
| Parent molecule | Erythropoietin, helix B domain |
| Residues | 11 |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| N-terminal residue | Pyroglutamate |
| CAS number | 1208243-50-8 |
| Molecular formula | C51H84N16O21 |
| Average mass | 1257.3 g/mol |
| Monoisotopic mass | 1256.5997 Da |
| Form | Lyophilized powder |
| Purity specification | >99% by HPLC |
Those values agree with PubChem CID 91810664, and the sequence matches the one the European Medicines Agency uses to name the substance in its orphan designation, L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser.
The name PHBSP encodes the two facts that matter. "Helix B surface peptide" says which part of EPO it came from, and "pyroglutamate" says the N-terminal residue is a cyclized glutamine rather than a free amine.
Why an EPO Derivative Does Not Act Like EPO
This is the point the compound is most often misunderstood on, and the explanation is structural rather than hand-waving.
Erythropoietin's effect on red cell production runs through a homodimeric EPO receptor: one EPO molecule engages two copies of the same receptor, which dimerize and signal. The regions of EPO that contact that receptor are well mapped, and helix B's outer face is not among them. It points away from the binding interface.
That observation is what made the compound possible. If the tissue-protective signaling attributed to EPO runs through a different receptor assembly from the erythropoietic signaling, then a peptide reproducing only the non-contacting surface should retain the first and lose the second. The literature describes that second assembly as a heteromer of the EPO receptor with the beta common receptor subunit CD131, and calls it the innate repair receptor.
The practical consequence is the opposite of what the provenance suggests. A researcher assuming an EPO-derived peptide raises hematocrit has the pharmacology backwards: the published work describes the compound as non-erythropoietic, and the 2010 paper in the Proceedings of the National Academy of Sciences that reported cardioprotection says so in its own title, describing a nonerythropoietic, tissue-protective peptide mimicking the three-dimensional structure of erythropoietin (PMID 20660739).

That said, non-erythropoietic is a statement about a measured activity in the published models, not a safety conclusion, and it says nothing about how any anti-doping authority treats the compound.
Status in Canada
| Question | Answer |
|---|---|
| Health Canada Drug Product Database entry | None for cibinetide as an ingredient |
| Authorized drug product in Canada | No |
| Canadian sites in a registered trial | None; the four registered trials ran in the United States, the Netherlands, Sweden and the United Kingdom |
| Supplied as | Research material, in vitro use only |
A search of Health Canada's Drug Product Database by active ingredient returns no product containing cibinetide. The Canadian rules that govern research peptides generally are set out in are peptides legal in Canada.
Status in the United States
| Question | Answer |
|---|---|
| FDA-approved drug product | No |
| On the 503A Bulks List | No |
| FDA compounding category, May 2026 | Category 3, nominated without adequate support |
| In the October 2026 HHS draft policy | No |
| Marketing authorization anywhere | No |
| Highest development phase reached | Phase 2 |
| Most recent registered trial start | 2016 |
| Supplied as | Research material, in vitro use only |
ARA-290 has never been an approved drug product. What makes its position unusual on this shelf is that it did enter formal clinical development with a named sponsor and registered trials, and then that development stopped. The public record does not say why. What it does show is that no registered trial has started since 2016, and that the last one to run, in Belfast, was stopped because its study drug expired and no replacement supply was available.
FDA's own paperwork records where it sits. The agency's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026, places "Cibinetide (ARA-290)" in Category 3: Bulk Drug Substances Nominated Without Adequate Support. That is a different and weaker position than the peptides that reached an advisory committee in July 2026: it means the nomination did not come with enough to evaluate. FDA's own explanation of the interim policy adds the consequence: substances in Categories 2 or 3 are not afforded enforcement discretion for compounding, even where a nomination is later updated, and substances nominated since 7 January 2025 are no longer sorted into categories at all. Cibinetide is also absent from the six peptides covered by the HHS draft enforcement discretion policy published on 30 October 2026.
A search of ClinicalTrials.gov returns four studies, and the detail is worth setting out rather than summarising:
| Trial | Condition | Phase | Enrolled | Ran | Status |
|---|---|---|---|---|---|
| NCT02039687 (Araim Pharmaceuticals) | Neuropathy of sarcoidosis | 2 | 64 | Jan 2014 to Feb 2015 | Completed |
| NCT02070783 (Leiden University Medical Center) | Emotional processing in healthy volunteers | 1/2 | 36 | Feb 2012 to Feb 2014 | Completed |
| NCT01933529 | Type 2 diabetes and prediabetes | 2 | 24 | Oct 2013 to Dec 2015 | Unknown |
| NCT06626971 (Belfast Health and Social Care Trust) | Diabetic macular oedema | 2 | 9 | Apr 2016 to Aug 2017 | Terminated |
- NCT02039687, a double-blind, placebo-controlled phase 2 study in sarcoidosis sponsored by Araim Pharmaceuticals at the Cleveland Clinic and Leiden University Medical Center, started January 2014, recorded as completed with results posted. Its registered primary endpoint is the change in corneal nerve fibre area at 28 days.
- NCT02070783, a phase 1/2 randomised study in 36 healthy volunteers of emotional and cognitive processing, sponsored by Leiden University Medical Center, started February 2012, recorded as completed. The registry lists "depression" as its condition keyword, but nobody enrolled had that diagnosis.
- NCT01933529, a phase 2 study in prediabetes and type 2 diabetes, started October 2013, status recorded as unknown.
- NCT06626971, a phase 2 study for diabetic macular oedema, sponsored by Belfast Health and Social Care Trust, started April 2016, recorded as terminated. The registry's stated reason is "Expiry of study drug - no replacement available", not a safety or efficacy finding. The study was registered with EudraCT and ISRCTN in 2015 and added to ClinicalTrials.gov in October 2024. Its results were published in 2020: of nine participants recruited, eight completed, and the primary measure, best corrected visual acuity at week 12, did not improve, nor did central retinal thickness; a vision-related questionnaire score did, and no serious adverse events or anti-cibinetide antibodies were recorded (PMID 32674280).
The largest of them enrolled 64 participants. No registered trial has a start date later than 2016, the highest phase reached is phase 2, and of the four studies one was terminated after enrolling nine participants and one has unknown status. The European Commission granted cibinetide orphan designation EU/3/13/1191 for the treatment of sarcoidosis on 7 October 2013, and the EMA register still lists it as positive, with sponsorship transferred to Araim Pharmaceuticals Europe Limited, Ireland, in April 2019. The same EMA record notes a United States orphan designation for neuropathic pain due to sarcoidosis. An orphan designation is a finding about a condition's rarity and a product's plausibility, not a marketing authorization, and it does not show that anything was proven.
A compound whose clinical programme has been quiet for a decade is in a different position from one in active development, and that is a material fact for anyone weighing how much published human evidence stands behind it.
What the Published Research Measured
Unlike most compounds on a research shelf, ARA-290 has small human trials behind it as well as animal work. Both deserve stating accurately, because the human data is real and it is also small and early.
The animal and model work, in its own terms:
- The 2010 PNAS paper reported cardioprotection in a model of ischemic myocardial damage by a nonerythropoietic peptide mimicking EPO's 3D structure (PMID 20660739), with a related 2011 report in Molecular Medicine (PMID 21170473).
- A 2011 paper in Diabetes reported protection against neuroglial and vascular degeneration in a diabetic retinopathy model (PMID 21911748).
- A 2011 paper in Anesthesiology reported long-lasting relief of neuropathic pain behaviour in rats, and no effect in mice lacking the beta common receptor, which is the most direct published evidence that the activity depends on that receptor subunit (PMID 21873879).
- A 2016 paper in Peptides reported that ARA 290 acted on the TRPV1 channel in rodent pain models (PMID 26774587), a second proposed mechanism that sits beside the receptor account rather than replacing it.
- A 2013 paper in Molecular Medicine reported suppression of coronary atherosclerosis by the helix B surface peptide (PMID 23648638).
- A 2015 review in Pharmacology and Therapeutics summarized the mechanism, describing long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin (PMID 25728128).
- A 2022 paper in Frontiers in Cardiovascular Medicine reported reduced cardiac inflammation and attenuated age-associated declines in heart function in an animal model (PMID 36741836).
The human work, in its own terms:
- A 2012 paper in Molecular Medicine reported a randomised, double-blind pilot study in 22 people with sarcoidosis and small fibre neuropathy symptoms, in which the small fibre neuropathy screening list score improved more than with placebo at week 4, while the Brief Pain Inventory and fatigue scores improved equivalently in both groups (PMID 23168581).
- A 2013 paper in Molecular Medicine reported that ARA 290 improved symptoms in patients with sarcoidosis-associated small nerve fiber loss and increased corneal nerve fiber density (PMID 24136731). The paper carries a 2016 erratum.
- A 2015 paper in Molecular Medicine reported a phase 2 study in type 2 diabetes with painful neuropathy, recording changes in HbA1c, lipid profile and a neuropathic symptom questionnaire over a 56-day observation period; its corneal nerve fibre density increase was reported only in the subgroup whose baseline density was more than one standard deviation below normal (PMID 25387363). It is the paper most search engines now cite for the compound.
- A 2015 paper in European Neuropsychopharmacology reported the Leiden healthy-volunteer study, which tested emotional processing as a model of antidepressant action (PMID 26431906); that is why its registry entry carries the condition keyword "depression".
- A 2020 paper in the Journal of Clinical Medicine reported the Belfast diabetic macular oedema study: single-arm, nine recruited and eight completed, with no improvement in the primary visual acuity measure or in central retinal thickness at week 12 (PMID 32674280).
- A 2017 paper in Investigative Ophthalmology and Visual Science reported that cibinetide improved corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain (PMID 28475703).
- A 2014 review in Expert Opinion on Investigational Drugs covers ARA 290 for small fiber neuropathy in sarcoidosis (PMID 24555851).
- A 2018 paper in Scientific Reports examined corneal nerve fiber size as a measure of therapeutic response in small fiber neuropathy (PMID 29549285).
One more item belongs on the record. In February 2026 Molecular Medicine retracted a 2012 paper reporting that the pyroglutamate helix B surface peptide attenuated acute kidney injury in an animal model (retraction note PMID 41749083). The compound's literature is small and comes largely from one group of collaborators, so a retraction inside it is material to how much weight the rest of the preclinical record can bear.
Those human studies share a design feature worth noting: a corneal nerve fibre measurement, made by confocal microscopy, is the recurring endpoint. It is objective and structural, which is a strength, and it is a surrogate rather than a clinical outcome, which is the limit. The 2017 study's own title describes improved corneal nerve fibre abundance, not restored sensation or reduced disability, and that distinction is the whole difference between a structural signal and a clinical benefit.
Important note: no phase 3 trial has been published, the compound holds no marketing authorization in any jurisdiction, and the registered development programme shows no trial starting after 2016.
What the Corneal Nerve Results Do and Do Not Show
This is the question the compound is searched for, and the accurate answer is narrower than the question. What the published human work shows is that, in small trials in people with sarcoidosis-associated small nerve fibre loss, a measure of corneal nerve fibre structure increased relative to placebo, and symptom scores improved on some instruments and not others. The largest of them, 64 participants over 28 days, is the one to read closely. Its primary endpoint, the placebo-corrected change in corneal nerve fibre area, reached significance in one of its three active arms, the middle one (P = 0.012), while the confidence intervals of the other two included zero; pain improved significantly in every group, placebo included (PMID 28475703). The results posted to ClinicalTrials.gov add a secondary measure that did not move in step: the mean change in intra-epidermal nerve fibre density, counted from skin biopsy, was largest in the placebo arm. That is a signal in a surrogate endpoint in a specific disease, with no clear exposure-response pattern, in trials of 64 participants and fewer.
What it does not show is any general change in nerve tissue, that the effect translates to other kinds of neuropathy, or that it persists. No phase 3 trial has tested any of that, and the registered programme has started nothing since 2016. Any page presenting ARA-290 as an established treatment has made the jump from the first paragraph to the second without evidence.
How to Verify an ARA-290 Lot
The pyroglutamate is the feature to confirm, and it is a subtle one. Pyroglutamate forms when a glutamine's side chain cyclizes onto the backbone nitrogen, releasing ammonia. Here it is intentional and part of the molecule. The difficulty is that the same cyclization is one of the most common spontaneous modifications in peptide chemistry, so the species is familiar to any laboratory as a degradation artifact. The consequence for verification is specific: a lot synthesized with a free N-terminal glutamine instead would be heavier by about 17 daltons, and a mass spectrometric identity check is what distinguishes the intended cyclized form from the unintended open one. Confirm which form the certificate reports.
Eleven residues puts purity in the weak-evidence band. Chromatographic purity detects truncation and deletion impurities, and a short chain produces relatively few. A high purity figure for an eleven-residue peptide is unremarkable and distinguishes little about identity, for the reasons chain length and counterion goes into.
Net peptide content answers a question purity does not. The molecule carries multiple ionizable side chains and is supplied as a salt, so the fraction of the powder that is peptide is what determines the mass you weighed out. Its charge balance is unusual: two glutamates and the C-terminal carboxyl against a single arginine and no free N-terminal amine, because the pyroglutamate has closed it. That leaves very few basic sites to carry a counterion, so the expected counterion fraction differs from that of a basic peptide of similar length, and a certificate's net peptide figure should be read with that in mind.
Ask about the reference standard. The monoisotopic mass is 1256.5997 Da. An identity check is a comparison against an expected value, so the useful certificate states both the measured figure and what it was compared against. The methods are set out in what actually proves a peptide sequence.
Check the three things that make a certificate checkable:
- The laboratory is named, with its report number.
- The lot number on the document matches the vial in your hand.
- The laboratory publishes a verification page where the report number can be looked up independently.
A certificate that names no laboratory, or whose lot number matches nothing on the container, is a document about some other material. Volta publishes its certificates as page images in its published certificate archive with the issuing laboratory's own verification link, and a certificate for the batch you receive is available on request. Those reports carry both HPLC and mass spectrometry results.
ARA-290 on the Shelf
ARA-290 is listed as a single 10 mg vial and appears in no multi-component product.
That is appropriate for a compound whose proposed mechanism runs through a specific receptor heteromer: there is no established rationale for pairing it with anything else on the shelf, and a combination vial would make its already-small evidence base harder rather than easier to reason about.
It is worth placing beside the other compounds here that are fragments of larger proteins, because the comparison is instructive. KPV is three residues of a thirteen-residue hormone and does not act at that hormone's receptors, as what is KPV peptide sets out. ARA-290 is eleven residues of a 165-residue glycoprotein and does not reproduce that protein's defining activity. In both cases the fragment behaves unlike its parent, and in both cases the market's instinct is to assume the opposite. A fragment inherits a provenance, not a pharmacology.
Frequently Asked Questions
What is ARA-290?
ARA-290, also called cibinetide, ARA290, PHBSP or HBSP (helix B surface peptide), is an eleven-residue peptide corresponding to a surface region of the helix B domain of erythropoietin, with a pyroglutamate N-terminus. Its CAS number is 1208243-50-8, its formula is C51H84N16O21 and its average mass is 1257.3 g/mol.
Is ARA-290 FDA-approved?
No. Cibinetide is not approved for any use in the United States. FDA's May 2026 compounding list places it in Category 3, substances nominated without adequate support, and it is not among the six peptides in the October 2026 HHS draft enforcement discretion policy.
How long did the ARA-290 trials run?
Weeks, not years. The sarcoidosis studies assessed their endpoints after 28 days and the terminated macular oedema study ran over 12 weeks. Those are trial durations, and no study measured how quickly anything changes.
What did the sarcoidosis trials actually measure?
Corneal nerve fibres by confocal microscopy, plus symptom scores. The 64-participant trial's registered primary endpoint was the change in corneal nerve fibre area at 28 days, which reached significance in one of three active arms; pain improved in all groups including placebo. The smaller studies reported corneal nerve fibre density and questionnaire scores. These are surrogate endpoints in one condition rather than an established clinical effect.
Does ARA-290 raise red blood cell counts like EPO?
The published work describes it as non-erythropoietic. The helix B outer surface is not part of EPO's contact interface with the erythropoietin receptor homodimer that drives red cell production, so a peptide reproducing only that surface does not reproduce that activity. Separating the two was the design objective.
What receptor is it proposed to act at?
The literature describes a heteromeric assembly of the erythropoietin receptor with the beta common receptor subunit CD131, referred to as the innate repair receptor, as distinct from the EPO receptor homodimer responsible for erythropoiesis.
Has ARA-290 been approved anywhere?
No. It has never held a marketing authorization in any jurisdiction. It entered formal clinical development and reached phase 2, and no registered trial has a start date after 2016.
Has it been tested in humans?
Yes, in six published studies: three in sarcoidosis-associated small fibre neuropathy, one in type 2 diabetes, one in diabetic macular oedema and one in healthy volunteers, with corneal nerve fibre measurement by confocal microscopy as the recurring endpoint. The largest enrolled 64 participants at two centres, in the United States and the Netherlands. The endpoint is a structural surrogate rather than a clinical outcome, and no phase 3 trial has been published.
Why does the pyroglutamate matter for verification?
Because the same cyclization that is intentional here is also one of the commonest spontaneous modifications in peptide chemistry. A lot made with a free N-terminal glutamine would be about 17 daltons heavier, and a mass spectrometric identity check is what tells the intended form from the unintended one.
What is the amino acid sequence of ARA-290?
pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser: eleven residues, the first a pyroglutamate. The European Medicines Agency names the substance by that sequence in its orphan designation, and it matches PubChem CID 91810664.
Does ARA-290 have orphan drug status?
In the European Union, yes: orphan designation EU/3/13/1191 for sarcoidosis, granted on 7 October 2013 and listed as positive on the EMA register. The EMA record also notes a United States orphan designation for neuropathic pain due to sarcoidosis. Orphan designation is not an approval.
Is ARA-290 approved in Canada?
No. Health Canada's Drug Product Database lists no product containing cibinetide, and none of the four registered trials had a Canadian site.
Sources
- US Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A" (categories list), updated 14 May 2026: Cibinetide (ARA-290) listed in Category 3.
- US Department of Health and Human Services. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Federal Register, 30 October 2026, FR Doc. 2026-22192.
- PubChem Compound Summary, CID 91810664 (Cibinetide). National Library of Medicine. Synonyms including ARA290 and PHBSP; CAS number, formula, average mass and monoisotopic mass as cited above.
- ClinicalTrials.gov, search for cibinetide and ARA-290, checked 14 November 2026 (four studies; results posted for NCT02039687): NCT02039687 (phase 2, Araim Pharmaceuticals, started 2014-01, completed), NCT02070783 (phase 1/2, Leiden University Medical Center, started 2012-02, completed), NCT01933529 (phase 2, started 2013-10, status unknown), NCT06626971 (phase 2, Belfast Health and Social Care Trust, started 2016-04, terminated).
- Proceedings of the National Academy of Sciences. 2010. "Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin." PMID 20660739.
- Anesthesiology. 2011;115(5):1084-92. "ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice." PMID 21873879.
- Molecular Medicine. 2012;18(1):1430-6. "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study." PMID 23168581.
- Molecular Medicine. 2015;20(1):658-66. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." PMID 25387363.
- European Neuropsychopharmacology. 2015;25(12):2289-99. "Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action." PMID 26431906.
- Peptides. 2016;76:73-9. "ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception." PMID 26774587.
- Journal of Clinical Medicine. 2020;9(7). "A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema." PMID 32674280.
- Molecular Medicine. 2026;32(1):31. "Retraction Note: Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury." PMID 41749083.
- European Medicines Agency. Orphan designation EU/3/13/1191, cibinetide, treatment of sarcoidosis. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191, retrieved 14 November 2026.
- Health Canada Drug Product Database, active ingredient search "cibinetide", retrieved 14 November 2026: no entries.
- US Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act", content current as of 14 May 2026, retrieved 14 November 2026.
- Molecular Medicine. 2011. "A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage." PMID 21170473.
- Diabetes. 2011. "Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy." PMID 21911748.
- Molecular Medicine. 2013. "Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin." PMID 23648638.
- Molecular Medicine. 2013. "ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density." PMID 24136731.
- Expert Opinion on Investigational Drugs. 2014. "ARA 290 for treatment of small fiber neuropathy in sarcoidosis." PMID 24555851.
- Pharmacology and Therapeutics. 2015. "Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin." PMID 25728128.
- Investigative Ophthalmology and Visual Science. 2017. "Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain." PMID 28475703.
- Scientific Reports. 2018. "Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy." PMID 29549285.
- Frontiers in Cardiovascular Medicine. 2022. "A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan." PMID 36741836.

